• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加拿大安大略省住院 COVID-19 患者的 4C 死亡率评分的外部验证:一项回顾性研究。

External validation of the 4C mortality score among COVID-19 patients admitted to hospital in Ontario, Canada: a retrospective study.

机构信息

Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada.

Waterloo Regional Campus, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Canada.

出版信息

Sci Rep. 2021 Sep 20;11(1):18638. doi: 10.1038/s41598-021-97332-1.

DOI:10.1038/s41598-021-97332-1
PMID:34545103
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8452633/
Abstract

Risk prediction scores are important tools to support clinical decision-making for patients with coronavirus disease (COVID-19). The objective of this paper was to validate the 4C mortality score, originally developed in the United Kingdom, for a Canadian population, and to examine its performance over time. We conducted an external validation study within a registry of COVID-19 positive hospital admissions in the Kitchener-Waterloo and Hamilton regions of southern Ontario between March 4, 2020 and June 13, 2021. We examined the validity of the 4C score to prognosticate in-hospital mortality using the area under the receiver operating characteristic curve (AUC) with 95% confidence intervals calculated via bootstrapping. The study included 959 individuals, of whom 224 (23.4%) died in-hospital. Median age was 72 years and 524 individuals (55%) were male. The AUC of the 4C score was 0.77, 95% confidence interval 0.79-0.87. Overall mortality rates across the pre-defined risk groups were 0% (Low), 8.0% (Intermediate), 27.2% (High), and 54.2% (Very High). Wave 1, 2 and 3 values of the AUC were 0.81 (0.76, 0.86), 0.74 (0.69, 0.80), and 0.76 (0.69, 0.83) respectively. The 4C score is a valid tool to prognosticate mortality from COVID-19 in Canadian hospitals and can be used to prioritize care and resources for patients at greatest risk of death.

摘要

风险预测评分是支持冠状病毒病(COVID-19)患者临床决策的重要工具。本文的目的是验证最初在英国开发的 4C 死亡率评分在加拿大人群中的有效性,并研究其随时间的表现。我们在安大略省南部 Kitchener-Waterloo 和 Hamilton 地区的 COVID-19 阳性住院患者登记处进行了一项外部验证研究。我们使用接受者操作特征曲线下面积(AUC)评估 4C 评分预测院内死亡率的有效性,并通过自举法计算 95%置信区间。该研究纳入了 959 名患者,其中 224 名(23.4%)在院内死亡。中位年龄为 72 岁,524 名患者(55%)为男性。4C 评分的 AUC 为 0.77,95%置信区间为 0.79-0.87。在预先定义的风险组中,总体死亡率分别为 0%(低危)、8.0%(中危)、27.2%(高危)和 54.2%(极高危)。AUC 的第 1、2 和 3 波值分别为 0.81(0.76,0.86)、0.74(0.69,0.80)和 0.76(0.69,0.83)。4C 评分是一种预测加拿大医院 COVID-19 死亡率的有效工具,可用于优先考虑死亡风险最高的患者的护理和资源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615a/8452633/3d489b080f51/41598_2021_97332_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615a/8452633/3d489b080f51/41598_2021_97332_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615a/8452633/3d489b080f51/41598_2021_97332_Fig1_HTML.jpg

相似文献

1
External validation of the 4C mortality score among COVID-19 patients admitted to hospital in Ontario, Canada: a retrospective study.加拿大安大略省住院 COVID-19 患者的 4C 死亡率评分的外部验证:一项回顾性研究。
Sci Rep. 2021 Sep 20;11(1):18638. doi: 10.1038/s41598-021-97332-1.
2
Community-acquired pneumonia severity assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability study.COVID-19 住院患者社区获得性肺炎严重程度评估工具:验证和临床适用性研究。
Clin Microbiol Infect. 2021 Jul;27(7):1037.e1-1037.e8. doi: 10.1016/j.cmi.2021.03.002. Epub 2021 Apr 2.
3
External validation of the 4C Mortality Score for patients with COVID-19 and pre-existing cardiovascular diseases/risk factors.COVID-19 合并心血管疾病/危险因素患者的 4C 死亡率评分的外部验证。
BMJ Open. 2021 Sep 8;11(9):e052708. doi: 10.1136/bmjopen-2021-052708.
4
External validation of the COVID-19 4C mortality score in an urban United States cohort.在一个美国城市队列中对 COVID-19 4C 死亡率评分进行外部验证。
Am J Med Sci. 2022 Oct;364(4):409-413. doi: 10.1016/j.amjms.2022.04.030. Epub 2022 Apr 30.
5
Generation and validation of in-hospital mortality prediction score in COVID-19 patients: Alba-score.新冠肺炎患者院内死亡率预测评分 Alba-score 的生成与验证。
Curr Med Res Opin. 2021 May;37(5):719-726. doi: 10.1080/03007995.2021.1891036. Epub 2021 Mar 12.
6
External validation of the 4C Mortality Score for hospitalised patients with COVID-19 in the RECOVER network.RECOVER 网络中 COVID-19 住院患者 4C 死亡率评分的外部验证。
BMJ Open. 2022 Apr 21;12(4):e054700. doi: 10.1136/bmjopen-2021-054700.
7
External validation of two clinical prediction models for mortality in COVID-19 patients (4C and NEWS2), in three centers in Medellín, Colombia: Assessing the impact of vaccination over time.在哥伦比亚麦德林的三个中心对两种用于预测 COVID-19 患者死亡率的临床预测模型(4C 和 NEWS2)进行外部验证:评估随着时间推移疫苗接种的影响。
Infect Dis Now. 2024 Aug;54(5):104921. doi: 10.1016/j.idnow.2024.104921. Epub 2024 May 3.
8
Characteristics and outcomes of hospital admissions for COVID-19 and influenza in the Toronto area.多伦多地区因 COVID-19 和流感住院的特征和结果。
CMAJ. 2021 Mar 22;193(12):E410-E418. doi: 10.1503/cmaj.202795. Epub 2021 Feb 10.
9
Development and external validation of a prediction risk model for short-term mortality among hospitalized U.S. COVID-19 patients: A proposal for the COVID-AID risk tool.美国住院 COVID-19 患者短期死亡率预测风险模型的开发和外部验证:COVID-AID 风险工具的建议。
PLoS One. 2020 Sep 30;15(9):e0239536. doi: 10.1371/journal.pone.0239536. eCollection 2020.
10
Performance of the CURB-65, ISARIC-4C and COVID-GRAM scores in terms of severity for COVID-19 patients.CURB-65、ISARIC-4C 和 COVID-GRAM 评分在 COVID-19 患者严重程度方面的表现。
Int J Clin Pract. 2021 Oct;75(10):e14759. doi: 10.1111/ijcp.14759. Epub 2021 Sep 3.

引用本文的文献

1
Performance of Risk Scores in SARS-CoV-2 Infection: A Retrospective Study.SARS-CoV-2感染风险评分的表现:一项回顾性研究
Int J Environ Res Public Health. 2025 Jul 23;22(8):1166. doi: 10.3390/ijerph22081166.
2
Validation of the age, neutrophil to lymphocyte ratio, C reactive protein score on 28 day mortality in the National COVID cohort collaborative.国家新冠队列协作组中年龄、中性粒细胞与淋巴细胞比值、C反应蛋白评分对28天死亡率的验证。
Sci Rep. 2025 Aug 2;15(1):28254. doi: 10.1038/s41598-025-08822-5.
3
Investigating the relationship between the immune response and the severity of COVID-19: a large-cohort retrospective study.

本文引用的文献

1
S-Gene Target Failure as a Marker of Variant B.1.1.7 Among SARS-CoV-2 Isolates in the Greater Toronto Area, December 2020 to March 2021.S 基因目标失败作为 2020 年 12 月至 2021 年 3 月大多伦多地区 SARS-CoV-2 分离株中 B.1.1.7 变体的标志物。
JAMA. 2021 May 25;325(20):2115-2116. doi: 10.1001/jama.2021.5607.
2
Regional Variability in COVID-19 Case Fatality Rate in Canada, February-December 2020.2020 年 2 月至 12 月加拿大 COVID-19 病死率的地域差异。
Int J Environ Res Public Health. 2021 Feb 14;18(4):1839. doi: 10.3390/ijerph18041839.
3
Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis.
探究免疫反应与新型冠状病毒肺炎严重程度之间的关系:一项大型队列回顾性研究
Front Immunol. 2025 Jan 8;15:1452638. doi: 10.3389/fimmu.2024.1452638. eCollection 2024.
4
At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods.采用统计和机器学习方法对国际住院 COVID-19 患者队列中的死亡率和肺栓塞进行入院时预测。
Sci Rep. 2024 Jul 16;14(1):16387. doi: 10.1038/s41598-024-63212-7.
5
COVID-19: The Development and Validation of a New Mortality Risk Score.新型冠状病毒肺炎:一种新的死亡风险评分的开发与验证
J Clin Med. 2024 Mar 22;13(7):1832. doi: 10.3390/jcm13071832.
6
ANCOC Score to Predict Mortality in Different SARS-CoV-2 Variants and Vaccination Status.用于预测不同SARS-CoV-2变体和疫苗接种状态下死亡率的ANCOC评分
J Clin Med. 2023 Sep 8;12(18):5838. doi: 10.3390/jcm12185838.
7
Utility of the 4C ISARIC mortality score in hospitalized COVID-19 patients at a large tertiary Saudi Arabian center.4C ISARIC死亡率评分在沙特阿拉伯一家大型三级中心住院的COVID-19患者中的效用。
Multidiscip Respir Med. 2023 Aug 4;18:917. doi: 10.4081/mrm.2023.917. eCollection 2023 Jan 17.
8
Comparison of different prognostic scores in estimating short- and long-term mortality in COVID-19 patients above 60 years old in a university hospital in Belgium.比利时一家大学医院中不同预后评分对60岁以上COVID-19患者短期和长期死亡率估计的比较。
Eur Geriatr Med. 2023 Oct;14(5):1125-1133. doi: 10.1007/s41999-023-00836-4. Epub 2023 Aug 3.
9
External validation of the ISARIC 4C Mortality Score to predict in-hospital mortality among patients with COVID-19 in a Canadian intensive care unit: a single-centre historical cohort study.加拿大重症监护病房 COVID-19 患者院内死亡率预测的 ISARIC 4C 死亡率评分的外部验证:一项单中心历史队列研究。
Can J Anaesth. 2023 Aug;70(8):1362-1370. doi: 10.1007/s12630-023-02512-4. Epub 2023 Jun 8.
10
Validation of the SACOV-19 score for identifying patients at risk of complicated or more severe COVID-19: a prospective study.SACOV-19 评分用于识别 COVID-19 并发症或更严重风险患者的验证:一项前瞻性研究。
Infection. 2023 Dec;51(6):1669-1678. doi: 10.1007/s15010-023-02041-8. Epub 2023 May 11.
COVID-19 重症和死亡的人群风险因素:一项全球系统回顾和荟萃分析。
PLoS One. 2021 Mar 4;16(3):e0247461. doi: 10.1371/journal.pone.0247461. eCollection 2021.
4
The Potential Future of the COVID-19 Pandemic: Will SARS-CoV-2 Become a Recurrent Seasonal Infection?新冠疫情的潜在未来:严重急性呼吸综合征冠状病毒2(SARS-CoV-2)会成为反复出现的季节性感染吗?
JAMA. 2021 Apr 6;325(13):1249-1250. doi: 10.1001/jama.2021.2828.
5
Characteristics and outcomes of hospital admissions for COVID-19 and influenza in the Toronto area.多伦多地区因 COVID-19 和流感住院的特征和结果。
CMAJ. 2021 Mar 22;193(12):E410-E418. doi: 10.1503/cmaj.202795. Epub 2021 Feb 10.
6
Comparing the 4C mortality score for COVID-19 to established scores (CURB65, CRB65, qSOFA, NEWS) for respiratory infection patients.将新型冠状病毒肺炎(COVID-19)的4C死亡评分与呼吸道感染患者的既定评分(CURB65、CRB65、qSOFA、NEWS)进行比较。
J Infect. 2021 Mar;82(3):414-451. doi: 10.1016/j.jinf.2020.10.015. Epub 2020 Oct 25.
7
Development and Validation of the Quick COVID-19 Severity Index: A Prognostic Tool for Early Clinical Decompensation.快速 COVID-19 严重程度指数的制定与验证:一种用于早期临床失代偿的预后工具。
Ann Emerg Med. 2020 Oct;76(4):442-453. doi: 10.1016/j.annemergmed.2020.07.022. Epub 2020 Jul 21.
8
Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study.系统评价和外部验证 22 种住院成人 COVID-19 预后模型:一项观察性队列研究。
Eur Respir J. 2020 Dec 24;56(6). doi: 10.1183/13993003.03498-2020. Print 2020 Dec.
9
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score.利用 ISARIC WHO 临床特征协议对因 COVID-19 住院的患者进行风险分层:4C 死亡率评分的制定和验证。
BMJ. 2020 Sep 9;370:m3339. doi: 10.1136/bmj.m3339.
10
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.